Antimonials in Experimental Infection of Mice by Grunberg, E. & Schnitzer, R. J.
E. GRUNBERG Chemotherapy Laboratories of Hoffmann-
R. J. SCHNITZER La Roche Inc., Nutley, New Jersey
A CHEMOTHERAPEUTIC STUDY OF ANTIMONIALS IN THE EXPERIMENTAL
INFECTION OF MICE WITH CRYPTOCOCCUS NEOFORMANS
The use of antimony compounds, particularly potassium antimonyl tartrate
(Tartar emetic), in Cryptococcosis has occasionally been mentioned in the
literature,2"' but no experimental study of the therapeutic rationale of the
use of antimonials in this infection has to our knowledge ever been under-
taken. It did not seem that Tartar emetic was of any therapeutic value, but
this should not reflect on the chemotherapeutic possibilities of the entire
class of antimony derivatives. In rather extensive investigations on the
therapeutic sensitivity of the chronic infection of mice with C. neoformans
carried out in this laboratory it was observed that certain antimonials do
indeed possess a marked effect in this otherwise resistant infection.
The active antimonials belong to the group of carbamylbenzene stibonic
acids, synthesized by Dr. N. Steiger8 of the Roche Chemical Research
Laboratories. The most active member of this series was (4-[/8-f-hydroxy-
ethylamino)ethylcarbamyl] benzene stibonic acid (I), designated Ro
2-3094.
H203Sbf>CONHC2H4NHC2H40H
(I)
The compound contains approximately 31 'o Sb and was used in the form
of its water soluble diethanolamine salt.
MATERIALS AND METHODS
Strain of C. neoformans. This strain was received through the courtesy of Dr. M.
Tager, Emory University, Atlanta, Georgia in 1947 and has been kept on glucose
Sabouraud agar slants ever since. Transfers were made as a rule every 2d or 3d day.
For the infection of mice 48-hour cultures in Sabouraud's broth were employed.
EXPERIMENTAL PROCEDURE
Mice of 18-22 g. from one colony were used in these experiments. The
animals were infected intra-abdominally with 0.5 ml. of a 48-hours C. neo-
formans broth culture corresponding to 1,000,000 to 2,000,000 viable organ-
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isms according to plate counts. This infection was fatal for an average of
80%fo of the animals within three weeks, with the majority of the animals
dying between the 10th and 14th day. The infected mice were divided into
groups of 10 to 20 animals. The treatment, always by the subcutaneous
route, was started within 5-10 minutes after the infection. In most experi-
ments one daily dose was given for 21 days. All animals that died at least
five days after the infection were autopsied, the organs were examined, and
cultures on Sabouraud agar taken which were read after 48 hours' incuba-
tion. On the 22d day all surviving animals were sacrificed, examined, and
cultured in the same way. The pathological lesions produced by the infection
used were most marked in the lungs. Liver and spleen showed little or no
gross involvement. The lungs showed a high degree of pathological change
in the form of numerous whitish nodules which tended to become confluent.
Therefore, the criteria on which evaluation of Ro 2-3094 and other com-
parative compounds was based were the gross lesions of the lungs and the
cultures derived from this organ. In several instances cultures were also
taken from the brain. Since the results of the brain cultures were almost
identical with those of the lungs, brain cultures were not taken regularly.
The extent of gross lung lesions and of the growth on agar slants was esti-
mated using the symbols 1 + to 3 +. In this type of grading 3 + indicated
widespread lesions in all pulmonary lobes and-in cultures-the complete
covering of the agar surface with confluent growth; 2 + and + signify
lower degrees of involvement and lighter growth of cultures. In cases where
very few and small lesions and not more than 20 colonies were seen, actual
counts were made and, for the purpose of averaging, designated as 0.5 + or
less. Absence of the lesions and growth on agar was marked as zero. The
average of the lesions and cultures was calculated from the sum of the
plus and minus symbols.
This evaluation was supplemented by the ratio c/t of average of lesions in
controls: average of lesions in treated animals, and the same ratio was cal-
culated from the results of the cultures. Inactive compounds had a ratio
close to 1.0. Activity was characterized by values of more than 2.0.
EXPERIMENTAL
TOXICITY OF RO 2-3094
The acute toxicity was determined by single injection into mice using the
subcutaneous and intravenous routes and in rabbits by intramuscular or
intravenous injection. The observation time was at least three days. The
results as given in Table 1 indicate that the compound showed the com-
paratively low toxicity characteristic for stibonic acids.
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Repeated daily drug administration of 50, 100, and 250 mg./kg. was well
tolerated by the majority of mice for periods up to three weeks. Rabbits
tolerated 10 intramuscular injections of 20 mg./kg. given alternately into
the right and left hind leg without symptoms of systemic toxic effects. How-
ever, the animals showed at autopsy the characteristic tissue necrosis which
almost invariably follows the injection of antimonials.
TABLE 1. ACUTE TOXICITY OF SINGLE DOSES OF Ro 2-3094
LDs0: mg./kg.a
Animal subcut. intramusc. intraven.
Mouse 591.0 ... 350.0
Rabbit .... 90.0 23.0
a The figures refer to the free stibonic acid.
TABLE 2. EFFECT OF ANTIMONIALS IN THE C. NEOFORMANS INFECTION OF MICE
Infection: approx. 1.5 x 10' viable cells
Therapy: subcut. injection daily for 21 days
Autopsy: 22d day
Dose: mg./kg. Survival Average Ratio c/tb
Compound comp'd Sb. rate' lesions culture lesions culture
T. emetic 5.0 1.83 0/10 2.5 2.9 0.96 0.96
Fuadin 37.5 5.10 2/10 2.2 2.7 1.09 1.03
Neostibosan 50.0 20.0 0/10 1.9 2.4 1.26 1.16
Ro 2-1160 100.0 36.0 0/10 2.3 2.5 1.04 1.12
Ro 2-3094 50.0 15.5 23/30 0.57 0.3 4.21 9.3
Controls .... .... 4/44 2.4 2.8 ...
a No. surviving: no. observed mice.
b Lesions in controls: lesions in treated mice.
Cultures in controls: cultures in treated mice.
ACTIVITY AGAINST C. NEOFORMANS
(a) In vitro. A survey of the literature showed clearly that in the case of
C. neoformans there is a very unsatisfactory correlation of activity in vitro,
which is frequently very high, and in vivo, where chemotherapeutic effects
are generally absent. Ro 2-3094, though not selected on the basis of in vitro
activity, possesses only a modest growth-inhibiting property. In the usual
dilution test in Sabouraud's glucose broth using 0.05 ml. of a 48-hour broth
culture as inoculum, the fungistatic concentration was found to be 0.5
mg./ml., a result which was in fair agreement with the value of 1.5 mg./ml.
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recently published by Carton and Liebig.8 Addition of 5%o goat serum did
not interfere with the activity in our experiments.
(b) In vivo. The stibonic acid Ro 2-3094 was compared with a group of
known antimonials, namely: potassium antimonyl tartrate (Tartar emetic),
antimony-pyrocatechol sodium disulfonate (Fuadin), as representatives of
tervalent Sb compounds, and with the pentavalent compounds: Neostibosan
is a mixture of the diethylamine salts of p-aminophenyl stibonic acid, p-
acetylaminophenyl stibonic acid and antimonic acid; Ro 2-1160 is a com-
bination of 2-carboxymethylmercaptobenzene stibonic acid and calcium salt.7
TABLE 3. SYNOPSIS OF 16 EXPERIMENTS WITH Ro 2-3094 IN THE
C. NEOFORMANS INFECTION OF MICE
Infection: 1 x 108 to 2 x 106 viable cells
Therapy: daily subcut. injection for 21 days; dose 50 mg./kg./day
Survival Average Ratio clt
Group rate' % lesions cuilture lesions culture
Treated 130/170 77.2 0.66 0.58 3.18 4.66
Controls 22/108 20.4 2.10 2.7 ... ...
aNo. surviving mice: no. observed mice.
These compounds, as well as Ro 2-3094, were given at a dose of approxi-
mately one-fifth of the tolerated dose as found at single administration.
The results as given in Table 2 show that only Ro 2-3094 exerted a
marked effect in the C. neoformans infection. This is shown by the high
survival rate and by the appreciable reduction in the extent of lung lesions
and of organisms recovered by culture as compared to controls and unsuc-
cessfully treated mice. As a rule 50%o or more of the animals were free of
lesions and gave negative cultures. This effect appeared to be independent
of the Sb content, if one compares the three stibonic acids which were given
in comparable doses. The tervalent antimonials cannot be used for such a
comparison.
It might also be mentioned that 15 additional antimonials, most of them
stibonic acids, have been tested, but only one of them, closely related to
Ro 2-3094, showed activity against C. neoformans and this in lesser degree.
The experiments with Ro 2-3094 have been repeated on different occa-
sions, altogether 16 times, and the same results were obtained with
negligible variations. A survey of these experiments is given in Table 3.
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The animals listed in this table also contain a group of 40 treated and 27
untreated mice in which cultures were taken from the brain. The results
were very similar to those obtained with the lungs. The average extent of
growth of the brain cultures from the untreated controls was 1.6, the cor-
responding value from the brain of the treated mice, 0.6. This gave a ratio
c/t of 2.7. That this value is lower than that obtained in the evaluation of
the lungs is due to the fact that average strength of the brain cultures was
as a rule lower than that of the lungs. In an additional series of experiments
we tried to increase the protective effect of Ro 2-3094 by increasing the dose
TABLE 4. INFLUENCE OF DIFFERENT DOSAGE SCHEDULES ON THE EFFECT
OF Ro 2-3094 IN THE C. NEOFORMANS INFECTION OF MICE
Infection: 1 x 108 to 1.5 x 108 viable cells
A: 250 mg./kg. daily for 21 days
B: 100 mg./kg. daily for 21 days
C: 250 mg./kg. 2 times a week for 3 weeks
D: 50 mg./kg. daily for 21 days
Autopsy: 22d day
Dosage Total Survival Average of Ratio clt
schedule dose: g./kg. ratea lesions cultures lesions cultures
A 5.2 8/10 0.2 0.1 11.5 28.0
B 2.1 8/10 0.28 0.73 8.2 4.0
C 1.5 6/10 0.37 0.9 6.2 3.1
D 1.05 15/20 0.52 0.85 4.4 3.3
Controls ... 0/18 2.3 2.8 ...
'No. surviving mice: no. observed mice.
of the drug. At the same time we attempted to reduce the frequency of
administration by giving higher doses, e.g. the tolerated dose, of the drug.
The results of this experiment in which four different dosage schedules
were used are compiled in Table 4.
It will be seen from this table that all four dosage schedules, covering total
doses of 5.2 to 1.05 g./kg., exerted the expected effect on the survival rate
which varied from 60%o to 80%o, while all untreated controls died. Slight,
statistically insignificant differences were observed in the extent of lesions.
The reduction of culture growth was significantly greater in group A (total
dose 5.2 g./kg.) than in the remaining groups treated with the lower doses
of2.1, 1.5, and 1.05 g./kg. The "P" values were less than 0.02 for the differ-
ence between groups A and B and less than 0.01 for the differences between
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A and C and A and D. This seemed to indicate that at least the influence of
the drug on the recovery of the organisms from the lungs was dependent on
the dose within the range of dosages tested.
In one experiment in which the observation time was extended another
three weeks after discontinuance of therapy (50 mg./kg. for 21 days)
delayed death occurred in the group of treated mice. Nine out of 10 mice
lived 27 days post-infection; seven of the mice died between the 30th and
40th day. Autopsy showed, however, that the extent of lung lesions and the
growth on agar had not increased as demonstrated by the average values of
0.6 for lesions and 1.0 for cultures. The corresponding figures for the con-
trols which had died within the first three weeks after the infections were
2.3 and 2.8, respectively. At present this observation cannot be fully dis-
cussed because we have not done Ro 2-3094 chronic toxicity experiments
on non-infected mice. Practically identical findings can be found in one
of the experiments with Fungicidin as reported by Hazen and Brown.'
Ro 2-3094 has not been tested so far in other fungus infections. The
only other chemotherapeutic property we found was a slight trypanocidal
activity in T. brucei infections which could, however, only be observed with
the dose of 500 mg./kg. which was toxic for half of the treated animals.
DISCUSSION
From the data of the experimental part, we have concluded that the
stibonic acid Ro 2-3094 under the conditions of the test exerts a marked
effect on survival time, pathology, and cultural recovery of the causative
agent in infections of mice with the strain of C. neoformans used in these
experiments. Only one closely related stibonic acid had a similar although
less consistent activity, while 18 additional organic antimonials and a
great number of synthetic compounds from different chemical classes failed
to show an influence in this infection. Ro 2-3094 seems, as far as can be
learned from the literature, the only synthetic product able to control the
C. neoformans infection, although sulfadiazine has been mentioned by Reilly
and Artman' as prolonging life in infected rats. Antibiotics of microbial
origin seemed more frequently to be efficacious in this fungus infection.
Streptomycin1'6 and penicillin' had some activity in experimental infections,
while Actidione,." Polymyxin B,8 and other antibiotics5 were without effect
in mice, although some of them, e.g. Actidione and Polymyxin B, may be
potentially useful in central nervous system cryptococcosis of humans.
High in vivo activity in cryptococcal infections is apparently limited to
Fungicidin. Effects very similar to those observed with Ro 2-3094 and with
occasionally longer lasting success were observed by Hazen and Brown.'
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SUMMARY
The stibonic acid Ro 2-3094, a member of the group of substituted carba-
mylbenzene stibonic acids, exerted a protective chemotherapeutic effect in
experimental infections of mice with C. neoformans and seems to be the
first synthetic compound to show a definite effect in this infection.
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